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develop thromboembolic complications [8] and/or recurrent
miscarriages [10].
One other woman with FXII deﬁciency had a very low
PAI-1 (plasminogen activator inhibitor) level and her OHPwas
below the mean for the control group. This may indicate that
the OHP test could be a useful diagnostic tool for global
assessments of overall thrombotic or hemorrhagic risk in
individuals with combined genetic defects.
Although the number of subjects is relatively small, we
believe that these results are promising and may indicate that
determination of OHP could be a method of choice for
recognizing prothrombotic conditions associated with FXII
deﬁciency and for distinguishing individuals with similarly low
FXII levels. It seems that this assay (rather than the simple
FXII concentration) could be used as a predictor of possible
thrombotic risk.
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Oral contraceptives (OC) increase the risk of venous throm-
bosis through changes in procoagulant, anticoagulant and
ﬁbrinolytic parameters [1]. Thrombin generation-based acti-
vated protein C (APC) sensitivity is a global test for the net
prothrombotic eﬀect and predicts the risk of venous thrombo-
sis [2,3].
Recently, concern has been raised about the thrombotic risk
of a new OC composed of 3 mg drospirenone (DRSP) and
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30 lg ethinylestradiol (Yasmin, Schering AG, Berlin,
Germany) [4]. Also, a recent study showed a four-fold
increased risk of thrombosis for users of OC containing
cyproterone acetate (CPA) compared with users of OC
containing levonorgestrel (LNG) and an 18-fold increased risk
compared with non-users [5,6].
It is desirable to predict the prothrombotic effect of new OC
prior to the occurrence ofmany cases of thrombosis. Therefore,
we compared the sensitivity to APC in users of drospirenone-
containing OC with that in users of other OC, some of which
are known to increase the risk of thrombosis (e.g. desogestrel-
or cyproterone acetate-OC).
Healthy women using the same type of OC for at least four
cycles were recruited by advertising in local newspapers, public
and university buildings, student houses and general practi-
tioner waiting rooms. Exclusion criteria were age (< 18 years)
and contraindications for OC use as stated by the World
Health Organization. Blood samples were drawn between days
18 and 21 of the menstrual cycle. After the blood draw DRSP-
or CPA-containing OC users were requested to switch to a
second-generationOC: 150 lgLNGand 30 lg ethinylestradiol
(Microgynon-30, Schering AG) and second- or third-genera-
tion OC users were asked to switch to the DRSP-containing
OC. A second blood draw was performed between days
18 and 21 of the fourth cycle after the change of OC type. The
Medical Ethics Committee of the Leiden University Medical
Center approved the study. All volunteers gave written
informed consent.
Normalized APC sensitivity ratios (nAPCsr) were deter-
mined by quantifying the effect of APC on thrombin genera-
tion (ETP-based APC-resistance test) as described previously
[2]. The APC-resistance test was performed in duplicate and
without knowledge of the OC used or any other participant’s
characteristics. The samples were analyzed in random order in
one series.
Between July and November 2002, 158 women aged
18–51 years were recruited. We excluded two women, one
because of a history of diabetes mellitus and one because of
a history of thrombosis. Forty-six women switched OC type
of whom 40 returned for a second blood draw. One
participant using a CPA pill was erroneously prescribed the
DRSP pill instead of a LNG-containing OC. Five women in
the group of switchers discontinued due to breast tender-
ness, increase in acne and hirsutism, pregnancy wish, a
previously unreported history of high blood pressure or
surgery. One woman was lost to follow-up. The various
groups of OC users did not differ with respect to age and
body mass index.
Users of OC containing DRSP or CPA had higher nAPCsr
than users of LNG-containing OC, respectively, 4.1 and 4.0 vs.
3.0 (Table 1). Similar results were found for users of desogestrel
(DSG)- or gestodene (GTD)-containing OC. In the 39 women
who changed pills, the nAPCsr altered correspondingly, i.e. it
increased when switching from LNG-OC to DRSP-OC and
decreased when switching from DRSP- or CPA-OC to LNG-
OC (Table 1). Exclusion of participants with the factor V
Leiden mutation (n ¼ 14) or the prothrombin 20210 A
mutation (n ¼ 5) did not materially change the mean nAPCsr:
DRSP-OC (3.7), CPA-OC (4.0), DSG-OC (3.9), GTD-OC
(3.4) and remained all markedly higher than in users of LNG-
OC (2.8).
In this study of prothrombotic effects among 156 healthy
users of various types of OC formulations, users of DRSP-
and CPA-containing OC were found more resistant to the
anticoagulant action of APC than users of LNG-containing
OC. In addition, we conﬁrmed previous results on prothrom-
botic effects of third-generation progestogen-containing OC
(DSG, GTD) [2]. The observations were not the result of
differences between women rather than between OC, as proved
by the results in women who switched OC. The prothrombotic
effect of DRSP- and CPA-containing OC, as measured by
APC-sensitivity, was similar to the effect of OC containing the
third-generation progestogens DSG and GTD, which have a
two-fold higher risk of thrombosis compared with LNG-
containing OC [1].
Our results conﬁrm that the thrombin generation-based
APC-resistance test discriminates between OC with a high risk
of thrombosis (CPA, DSG and GTD) and OC with a lower
thrombotic risk (LNG) [3]. It is therefore an excellent test to
predict the thrombotic safety of OC before women experience
an actual thrombosis. In our study, DRSP-containing OC
users were less sensitive to APC than LNG-containing OC
users, which predicts an increased risk of thrombosis. There-
fore, even in the absence of clinical outcome data, we advise not
Table 1 Mean ETP-based nAPCsr in women using oral contraceptives containing diﬀerent kind of progestogens
Progestogen type N nAPCsr 95% CI
Progestogen type
N
nAPCsr
Switch to Before After Diﬀerence 95% CI
Levonorgestrel 60 2.99 2.71–3.27 Drospirenone 14 3.13 3.60 + 0.46 0.16–0.76
Drospirenone 23 4.13 3.53–4.74 Levonorgestrel 5 3.55 2.73 ) 0.83 ) 1.80–0.15
Cyproterone acetate 22 4.00 3.74–4.26 Levonorgestrel 6 3.96 3.01 ) 0.96 ) 1.66 to – 0.26
Desogestrel 33 4.07 3.71–4.43 Drospirenone 8 3.78 3.97 + 0.19 ) 0.11–0.49
Gestodene 12 3.66 3.04–4.29 Drospirenone 3 2.78 2.79 + 0.01 ) 2.45–2.47
Norgestimate 4 5.24 3.13–7.36 Drospirenone 2 4.61 4.93 + 0.31 ) 0.99–1.62
Norethindrone 2 3.62 2.15–5.08 Drospirenone 1 3.73 2.36 ) 1.38 –
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to prescribe DRSP-containing combined OC as a ﬁrst choice
for women starting OC.
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Thalidomide has been employed in recent years for its anti-
inﬂammatory and antiangiogenic properties in the treatment of
several conditions including leprosy, systemic lupus erythema-
tosus (SLE), Behcet’s disease (BD) and solid and hematological
malignancies [1,2].
An increased incidence of deep venous thrombosis (DVT)
has been observed in malignancies, especially in multiple
myeloma, during treatment with thalidomide combined with
chemotherapy. Pathogenetic mechanisms of thalidomide asso-
ciated DVT have not been clearly assessed. A possible role for
acquired APC-R, increased levels of factor VIII coagulant
activity, von Willebrand factor antigen and vascular endothel-
ial growth factor has been suggested. The role of thrombophilia
is unclear [3,4].
We describe a case of proximal DVT in a patient with SLE
treated with thalidomide for cutaneous vasculitis.
A 65-year-old female satisﬁed the American College of
Rheumatology criteria for SLE. Recurrent cutaneous vasculitis
had been observed during a period of 5 years. Her medical
history was remarkable for obesity, varicose veins and venous
thromboembolism, having suffered of recurrent idiopathic
superﬁcial thrombophlebitis of lower limbs in the last 2 years.
She had been treated with corticosteroids for 3 years.
In an attempt to spare corticosteroids, thalidomide (100 mg)
was added. Fifteen days later the patient presented right lower
limb swelling, pain and discomfort. No chest pain, dyspnea or
hemoptysis was reported. Venous ultrasonography of the lower
limbs was diagnostic for proximal DVT (right superﬁcial
femoral/popliteal vein) associated with recurrence of superﬁcial
thrombophlebitis (great saphenous vein). A perfusional lung
scintigraphy was negative for signs of pulmonary embolism.
The search for antiphospholipid antibodies (lupus anticoagu-
lant, anticardiolipin antibodies, antibeta2-GPI antibodies), FV
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